
Experience
Cooley Advises Investor Syndicate on $2.25 Billion Acquisition of HistoSonics
August 7, 2025
Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.
Related contacts
Related Practices & Industries
Drata Announces Acquisition of SafeBase
February 10, 2025
Cooley advised Drata, a trust management platform, on its definitive agreement to acquire SafeBase, a trust center platform designed for friction-free security reviews.
Related contacts
Related Practices & Industries
Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion
November 26, 2024
Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.
Related contacts
Related Practices & Industries
Chimagen Biosciences Announces Sale of CMG1A46 to GSK
October 29, 2024
Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.
Related contacts
Related Practices & Industries
Longboard Pharmaceuticals Announces $2.6 Billion Sale to Lundbeck
October 14, 2024
Cooley advised Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.
Related contacts
Related Practices & Industries
Related news and events
Cooley Advises Investor Syndicate on $2.25 Billion Acquisition of HistoSonics
Admissions and credentials
New York
California
Memberships and affiliations
American Bar Association (ABA)